<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Etiology and diagnosis of coagulopathy in trauma patients
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Etiology and diagnosis of coagulopathy in trauma patients
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Etiology and diagnosis of coagulopathy in trauma patients
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Matthew E Kutcher, MD, MS, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mitchell J Cohen, MD, FACS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eileen M Bulger, MD, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lawrence LK Leung, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kathryn A Collins, MD, PhD, FACS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 02, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H62323431">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Trauma remains a leading cause of death and disability in adults in spite of advances in resuscitation, surgical management, and critical care [
         <a href="#rid1">
          1
         </a>
         ]. Even though improved efficiency of trauma systems military and civilian has reduced the time interval between acute injury and treatment, between 25 and 35 percent of injured civilian trauma patients develop a biochemically evident coagulopathy upon arrival in the emergency department [
         <a href="#rid2">
          2-4
         </a>
         ].
        </p>
        <p>
         Coagulopathy may be the result of physiologic derangements such as acidosis, hypothermia, or hemodilution related to fluid or blood administration; however, an acute coagulopathy can also occur in severely injured patients independent of, or in addition to, these factors [
         <a href="#rid2">
          2,3
         </a>
         ]. Several terms are used in the literature to refer to this latter condition, including trauma-induced coagulopathy (TIC), acute traumatic coagulopathy (ATC), early coagulopathy of trauma (ECT), and the acute coagulopathy of trauma-shock (ACoTS) [
         <a href="#rid2">
          2,3,5-7
         </a>
         ]. Based on the terminology used by the International Society for Thrombosis and Haemostasis, we will use the term TIC in this review [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         The early identification and treatment of patients with coagulopathy is an important aspect of damage control and resuscitation, which consists of permissive hypotension; avoidance of excessive crystalloid, preventing and treating hypothermia, and acidosis; rapid surgical correction of anatomic hemorrhage; and early transfusion using a balanced transfusion strategy [
         <a href="#rid9">
          9-15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15148.html" rel="external">
          "Overview of damage control surgery and resuscitation in patients sustaining severe injury"
         </a>
         .)
        </p>
        <p>
         The etiology and diagnosis of coagulopathy associated with trauma will be reviewed here. The general principles of shock management in the trauma patient and the treatment of excessive anticoagulation related to medical treatment are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/113837.html" rel="external">
          "Initial management of moderate to severe hemorrhage in the adult trauma patient"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/117817.html" rel="external">
          "Ongoing assessment, monitoring, and resuscitation of the severely injured patient"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H62326298">
         <span class="h1">
          IMPACT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coagulopathy in trauma patients, and specifically trauma-induced coagulopathy as an acute systemic phenomenon, is associated with higher transfusion requirements, longer intensive care unit and hospital stays, more days requiring mechanical ventilation, and a greater incidence of multiorgan dysfunction.
        </p>
        <p>
         Approximately 25 percent of patients admitted to civilian level I trauma centers receive transfused blood, with approximately 80 percent of these receiving fewer than 10 units. Massive transfusion (traditionally defined as &gt;10 units packed red blood cells over 24 hours) is required in 2 to 3 percent of injured patients [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Compared with patients who do not have coagulopathy, those with coagulopathy have a threefold to fourfold greater mortality and are up to eight times more likely to die within the first 24 hours following injury [
         <a href="#rid2">
          2-4,17,18
         </a>
         ]. Most deaths in trauma patients due to in-hospital hemorrhage occur within six hours of admission [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H62326162">
         <span class="h1">
          ETIOLOGIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The etiology of coagulopathy in the injured patient is multifactorial with overlapping contributing etiologies depending upon the injury and nature of resuscitation. Normal coagulation is a balance between hemostatic and fibrinolytic processes that permit control of bleeding following mild injury while preventing inappropriate intravascular thrombosis. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis"
         </a>
         .)
        </p>
        <p>
         Etiologies that upset the normal balance include classic elements of the "vicious triad": acidosis related to tissue injury and shock, hypothermia from exposure and fluid administration, and hemodilution due to fluid or component blood product administration. Systemic consumption of clotting factors manifesting as disseminated intravascular coagulation may occur early after injury due to inadequate clotting factor repletion in the face of ongoing consumption, or later in the hospital course triggered by secondary insults (eg, sepsis). Distinct from these elements, trauma-induced coagulopathy (TIC) is a multifactorial biochemical response to tissue injury and shock mediated by dysregulated coagulation, altered fibrinolysis, systemic endothelial dysfunction, inflammatory responses to injury, and platelet dysfunction. Injury to brain tissue may predispose to TIC, and approximately one-third of patients with traumatic brain injury (TBI) have a coagulopathy, although whether TBI-associated coagulopathy is fundamentally different from injury-related coagulopathy is not clear [
         <a href="#rid21">
          21-23
         </a>
         ]. (See
         <a class="local">
          'Trauma-induced coagulopathy'
         </a>
         below.)
        </p>
        <p>
         A prospective study of injured patients with blunt trauma and hemorrhagic shock enrolled in the Host Response to Injury Large-Scale Collaborative Program attempted to characterize the relative contributions of multiple risk factors to coagulopathy in 578 of the 1537 patients (37.6 percent). In this study, more than 80 percent of patients with coagulopathy on arrival had risk factors related to elements of the classic vicious triad as well as to TIC. The authors found that, even when adjusting for all of these risk factors in multivariate analysis, arrival coagulopathy remained an independent predictor of multiorgan failure and mortality, implying that additional biochemical factors driving coagulopathy remain to be discovered [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H83047596">
         <span class="h2">
          Acidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inadequate tissue perfusion in patients with hypovolemic shock due to bleeding leads to metabolic (lactic) acidosis, which can be exacerbated by excessive chloride and component blood administration. (See
         <a class="medical medical_review" href="/z/d/html/1594.html" rel="external">
          "Definition, classification, etiology, and pathophysiology of shock in adults"
         </a>
         .)
        </p>
        <p>
         Acidosis causes demonstrable clotting dysfunction in experimental models at pH &lt;7.2 by interfering with the assembly of coagulation factor complexes involving calcium and negatively charged phospholipids [
         <a href="#rid25">
          25-28
         </a>
         ]. As an example, the activity of the factor Xa/Va/phospholipid/prothrombin ("prothrombinase") complex is reduced by 50, 70, and 90 percent at a pH of 7.2, 7.0, and 6.8, respectively. However, correction of acidosis alone does not always correct the associated coagulopathy, indicating that tissue injury causes coagulopathy via additional mechanisms [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H299161">
         <span class="h2">
          Hypothermia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypothermia following injury is due to cold exposure at the time of injury, during transport, and during the trauma examination compounded by the administration of cold intravenous fluids. Nearly two-thirds of trauma patients have a temperature below 36°C on presentation; 9 percent of trauma patients have a temperature at or below 33°C [
         <a href="#rid27">
          27,31-34
         </a>
         ]. Hypothermia in injured patients is graded as mild (36 to 34°C), moderate (34 to 32°C), or severe (&lt;32°C) [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
         Patients who require surgery are at a greater risk for hypothermia due to further physical exposure in the operating room, additional fluid administration, and the effects of general anesthesia. Injured patients with hypothermia generally have worse outcomes compared with non-injured patients with hypothermia; however, hypothermia alone is a weak independent predictor of mortality [
         <a href="#rid35">
          35,36
         </a>
         ]. Acidosis and hypothermia are synergistic with increased mortality when both are present, compared with either alone [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
         The effect of hypothermia on clotting includes platelet dysfunction and impaired enzymatic function. Overall thrombin generation in activated in vitro clotting systems is generally preserved at a temperature of 33°C; however, impairment of tissue factor activity, platelet aggregation, and platelet adhesion is evident at temperatures between 33 to 37°C [
         <a href="#rid27">
          27,31
         </a>
         ]. It is important to note that no effects on coagulation tests (either standard or viscoelastic) are seen in hypothermia-induced coagulopathy without special sample handling due to the standard practice of prewarming blood samples to 37°C prior to analysis, which corrects the defect. In other words, the result of coagulation testing reflects clotting characteristics that the patient would have if his/her temperature were 37°C.
        </p>
        <p>
         Specific measures to correct hypothermia include controlling physical exposure, administration of warmed fluids, and passive rewarming with blankets and forced-air devices. Rapid identification and control of bleeding is vital to preserve normal temperature. Continuous temperature monitoring is essential to ensure that mild hypothermia does not worsen. In the case of moderate or severe hypothermia and coagulopathy, central rewarming may be needed. (See
         <a class="medical medical_review" href="/z/d/html/94588.html" rel="external">
          "Perioperative temperature management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H299168">
         <span class="h2">
          Resuscitation-associated coagulopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Resuscitation-associated coagulopathy (RAC), also now termed iatrogenic coagulopathy, refers to alterations of the coagulation system induced by large volumes of intravenous fluids or unbalanced component blood administration during the management of shock [
         <a href="#rid38">
          38
         </a>
         ]. The age of blood may contribute to RAC.
        </p>
        <p>
         Trauma resuscitation historically focused on the treatment of hypotension and acidosis with aggressive crystalloid resuscitation followed by packed red blood cells (PRBCs). At that time, treatment of coagulopathy was initiated only in response to abnormal standard coagulation tests. Similarly, platelet transfusion was generally not performed until laboratory evidence of thrombocytopenia was present. Computer modeling [
         <a href="#rid39">
          39
         </a>
         ], in vitro experiments [
         <a href="#rid40">
          40
         </a>
         ], and clinical studies in healthy volunteers confirm that large-volume resuscitation with crystalloid, colloid, and packed red blood cells leads to dilution of plasma clotting proteins [
         <a href="#rid41">
          41
         </a>
         ]. A retrospective study of 8724 injured patients from the German Trauma Registry found a positive correlation between prehospital fluid resuscitation volume and coagulopathy [
         <a href="#rid4">
          4
         </a>
         ]. Coagulopathy was present on admission in more than 50 percent of patients who received &gt;3 L of intravenous fluid prior to arrival, but coagulopathy was also present in 10 percent of patients administered &lt;500 mL and in 32 patients who had received no prehospital fluids, which appears to reflect the frequently overlapping contribution of TIC. (See
         <a class="local">
          'Trauma-induced coagulopathy'
         </a>
         below.)
        </p>
        <p>
         Prolonged storage of packed red blood cell units prior to transfusion has been previously suggested to significantly contribute to RAC. The effects of prolonged storage (referred to as the "storage lesion") include decreased pH, chelation of calcium, low 2,3-diphosphoglycerate levels, and decreased clotting factor concentration. The median duration of storage of a unit of red blood cells in the United States is approximately 15 days, with older units frequently allocated to high-use facilities such as trauma centers [
         <a href="#rid42">
          42
         </a>
         ]. Thus, it was suggested that transfusion of older blood impaired microvascular perfusion and had inflammatory and immunomodulatory effects, which would be particularly relevant for massively transfused trauma patients. While early observational studies suggested that an older storage age of transfused PRBCs was linked to higher morbidity and mortality, the available data suggest similar mortality for transfusion of "fresh" red blood cell units (stored for fewer days) compared with "standard issue" red blood cell units (stored for the usual number of days) [
         <a href="#rid43">
          43-48
         </a>
         ]. Overall, given the logistical and resource challenges related to preferential use of "fresh" red blood cells in the context of a lack of high-quality data to support this practice, standard blood age-related transfusion practices are appropriate for injured patients and are generally not felt to exacerbate underlying coagulopathy in a clinically relevant manner. (See
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Changes during in vitro storage'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7939.html" rel="external">
          "Practical aspects of red blood cell transfusion in adults: Storage, processing, modifications, and infusion", section on 'Donor and component characteristics potentially affecting recipient outcome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H83047881">
         <span class="h2">
          Disseminated intravascular coagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Disseminated intravascular coagulation (DIC) is a systemic process producing a consumptive coagulopathy in concert with diffuse microvascular thrombosis  (
         <a class="graphic graphic_table graphicRef63831" href="/z/d/graphic/63831.html" rel="external">
          table 1
         </a>
         ). In trauma patients, tissue-injury-induced exposure of tissue factor and activation of the extrinsic coagulation cascade leads to thrombin generation proportional to injury severity [
         <a href="#rid49">
          49
         </a>
         ]. In addition, systemic embolism of tissue-specific thromboplastins from sites of injury (including bone marrow lipid material, amniotic fluid, and brain phospholipids) may predispose patients to DIC [
         <a href="#rid50">
          50
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1306.html" rel="external">
          "Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Acute versus chronic DIC'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H122599087">
         <span class="h2">
          Trauma-induced coagulopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         TIC is an impairment of hemostasis and activation of fibrinolysis that occurs early after injury and is biochemically evident prior to, and independent of, the development of significant acidosis, hypothermia, or hemodilution. The risk of TIC increases with hypotension, higher injury severity score, worsening base deficit, and head injury [
         <a href="#rid3">
          3,17,18
         </a>
         ]. Once established, TIC is often compounded by the other etiologies of coagulopathy. (See
         <a class="local">
          'Acidosis'
         </a>
         above and
         <a class="local">
          'Hypothermia'
         </a>
         above and
         <a class="local">
          'Resuscitation-associated coagulopathy'
         </a>
         above.)
        </p>
        <p>
         Patients with TIC frequently meet criteria for DIC, and some authors have argued that TIC may represent an early, partially compensated stage of DIC [
         <a href="#rid38">
          38,51,52
         </a>
         ]. However, the concept of DIC as a final common pathway for several different phenomena is insufficient to explain the hematologic abnormalities post-injury [
         <a href="#rid17">
          17,53,54
         </a>
         ]. Coagulopathy in the absence of thrombocytopenia and hypofibrinogenemia, as seen in TIC , argues against consumption as a necessary underlying mechanism [
         <a href="#rid29">
          29
         </a>
         ] Although D-dimer levels are frequently elevated and fibrinogen levels depleted in acutely injured patients, indicating intravascular fibrin deposition and active fibrinolysis [
         <a href="#rid55">
          55
         </a>
         ], functional thrombin generation (assayed by the presence of prothrombin fragments and thrombin-antithrombin complexes) remains intact [
         <a href="#rid17">
          17,56-58
         </a>
         ]. Furthermore, TIC occurs only when tissue injury is combined with systemic hypoperfusion. Thus, it is most likely that TIC is mechanistically distinct from DIC but that these frequently overlap. Exploring this distinction is an area of ongoing research.
        </p>
        <p class="headingAnchor" id="H18982251">
         <span class="h3">
          Dysregulated coagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Under normal circumstances, tissue injury leads to thrombin generation, fibrin deposition, and clot formation via the extrinsic pathway  (
         <a class="graphic graphic_figure graphicRef75450" href="/z/d/graphic/75450.html" rel="external">
          figure 1
         </a>
         ). The enzymatic pathways making up the coagulation cascade are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1371.html" rel="external">
          "Overview of hemostasis"
         </a>
         .)
        </p>
        <p>
         Initiation of the clotting process is localized to the site of tissue injury. Systemic coagulation due to the escape of thrombin from the injury site is inhibited by circulating antithrombin III, or by the binding of thrombin to constitutively expressed thrombomodulin on nearby undamaged endothelial cells [
         <a href="#rid59">
          59
         </a>
         ]. Protein C, a systemic anticoagulant, is proteolytically converted from an inactive zymogen to activated protein C (aPC) by the complex of thrombin with thrombomodulin. aPC is a serine protease that proteolytically inactivates factors Va and VIIIa and depletes plasminogen inhibitors  (
         <a class="graphic graphic_figure graphicRef81428" href="/z/d/graphic/81428.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_table graphicRef70156" href="/z/d/graphic/70156.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid60">
          60,61
         </a>
         ]. In this manner, aPC can serve a protective function by inhibiting thrombosis during periods of decreased flow.
        </p>
        <p>
         Initial observations in hypoperfused trauma patients found a correlation between TIC and elevated levels of aPC, reduced levels of non-activated protein C, and elevated soluble thrombomodulin [
         <a href="#rid17">
          17,62
         </a>
         ]. In a multicenter observational study of 165 critically injured trauma patients with serial plasma clotting factor analysis, injury severity and shock were associated with elevation of aPC and reduction of all analyzed clotting factors. Multivariate analysis identified deficits in fibrinogen, thrombin, Factor V, Factor VIII, Factor IX, Factor X, and aPC levels as principal drivers of coagulopathy [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3258619303">
         <span class="h3">
          Alterations in fibrinolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endothelial release of tissue plasminogen activator (tPA) is stimulated by both hypoperfusion-related hypoxia, as well as the negative feedback mechanism associated with thrombin generation. Consumption of endogenous plasminogen activator inhibitor-1 (PAI-1) by TIC-mediated aPC further destabilizes the fibrinolytic balance, leading to uninhibited tPA-mediated conversion of plasminogen to plasmin [
         <a href="#rid64">
          64
         </a>
         ]. Diversion of thrombin to protein C activation may also reduce activation of thrombin-activatable fibrinolysis inhibitor (TAFI), further enhancing fibrinolytic activity [
         <a href="#rid65">
          65
         </a>
         ]. These mechanisms lead to the relative hyperfibrinolysis seen in trauma patients with TIC, which is reflected in increased levels of tPA, decreased PAI-1, and increased D-dimer [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="local">
          'D-dimer'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4152690793">
         <span class="h3">
          Systemic endothelial dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tissue injury and shock are also associated with degradation of the endothelial glycocalyx, a protective endothelial layer. Loss of glycocalyx integrity is reflected by the systemic release of syndecan-1, a glycocalyx degradation product, which has been shown to correlate with coagulopathy and mortality [
         <a href="#rid66">
          66,67
         </a>
         ]. Shedding of endogenous heparan sulfates from the glycocalyx can also lead to auto-anticoagulation via increased circulating endogenous heparinoids [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         The overall degree of glycocalyx damage correlates with post-injury catecholamine levels [
         <a href="#rid69">
          69
         </a>
         ]. Profound activation and consumption of protein C can deplete protein C stores, potentially leading to reduced endothelial protective signaling via the aPC receptors protease-activated receptor-1 (PAR-1) and endothelial protein C receptor (EPCR) independently of aPC's role as an anticoagulant, potentially exacerbating endothelial dysfunction [
         <a href="#rid70">
          70
         </a>
         ]. Suggesting the clinical relevance of this mechanism, one prospective study noted that protein C depletion in trauma patients correlated with elevated markers of endothelial injury and coagulopathy and with a threefold higher risk of mortality [
         <a href="#rid66">
          66
         </a>
         ]. Several ongoing studies are evaluating the relevance of the protein C system to endothelial activation and barrier permeability [
         <a href="#rid71">
          71-74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H351228710">
         <span class="h3">
          Inflammatory responses to injury
         </span>
         <span class="headingEndMark">
          —
         </span>
         APC also has anti-inflammatory and cytoprotective effects. In a single-center study of 203 critically injured trauma patients, early coagulopathy was linked to high levels of aPC, and later, protein C depletion as early as six hours after injury [
         <a href="#rid62">
          62
         </a>
         ]. Patients who demonstrated protein C depletion had a significantly increased risk of acute lung injury, ventilator-associated pneumonia, multiorgan failure, and death. [
         <a href="#rid70">
          70
         </a>
         ]The importance of these mechanisms is suggested by separate murine models in trauma and sepsis. In these experiments, selective antibody-mediated inhibition of the anticoagulant function of aPC reduced the rate of coagulopathy, but not mortality, while inhibition of anticoagulant and cytoprotective functions increased mortality after a challenge with trauma/hemorrhagic shock [
         <a href="#rid60">
          60
         </a>
         ], or injection of lipopolysaccharide [
         <a href="#rid75">
          75
         </a>
         ]. Cytoprotective functions of aPC may also play a role in pulmonary capillary endothelial barrier function as suggested by in vitro studies [
         <a href="#rid71">
          71,76
         </a>
         ], and human studies associating persistently low protein C levels in critically injured, mechanically ventilated trauma patients with increased rates of pneumonia [
         <a href="#rid77">
          77
         </a>
         ]. Ongoing studies are evaluating the interactions of the protein C system and innate [
         <a href="#rid78">
          78,79
         </a>
         ] and cellular immunity [
         <a href="#rid71">
          71-74,80,81
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4252595159">
         <span class="h3">
          Platelet dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Platelets play a pivotal role in hemostasis after injury [
         <a href="#rid82">
          82
         </a>
         ]. Platelet count at the time of admission has been noted to inversely correlate with transfusion and early mortality in injured patients, even for platelet counts well in the normal range [
         <a href="#rid83">
          83
         </a>
         ]. Such quantitative platelet defects also correlate with progression of intracranial hemorrhage and mortality after traumatic brain injury [
         <a href="#rid84">
          84
         </a>
         ]. Several descriptive studies have also noted qualitative platelet dysfunction in trauma patients, reflecting functional platelet impairment that is independent of platelet count. In a prospective study of impedance aggregometry in 101 trauma patients, primary platelet dysfunction (ie, not due to preinjury
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         or
         <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">
          clopidogrel
         </a>
         use) occurred in 46 percent of patients on admission, and 91 percent of patients at some point during their hospital stay [
         <a href="#rid85">
          85
         </a>
         ]. Similar results were seen in studies of brain-injured trauma patients, which identified that aspirin-induced, but not primary trauma-induced, platelet dysfunction improved with platelet transfusion [
         <a href="#rid86">
          86,87
         </a>
         ]. However, other studies question the clinical utility of platelet aggregometry, reporting that aggregometry does not correlate with the need for platelet transfusion [
         <a href="#rid88">
          88
         </a>
         ], and that platelet transfusion does not in fact improve aggregometry results in injured patients [
         <a href="#rid89">
          89
         </a>
         ]. Further studies on the clinical utility of platelet functional testing and on optimal therapy for platelet dysfunction are needed [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H489139545">
         <span class="h2">
          Emerging effectors of coagulopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the mechanisms driving injury-associated coagulopathy, areas of emerging research suggest additional factors influencing coagulopathy associated with injury.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Release of microparticles
         </strong>
         – Preliminary work suggests that tissue injury may prompt release of thrombin-rich microparticles into the systemic circulation, the local effects of which may contribute to hemostasis, while wider systemic release may lead to a DIC-like phenotype tipping the balance toward coagulopathy. Studies have correlated the presence of cell-derived microparticles in the systemic circulation following injury. One prospective observational study of 180 trauma patients identified elevated levels of endothelial-, erythrocyte-, and leukocyte-derived microparticles into the circulation compared with 65 controls [
         <a href="#rid91">
          91
         </a>
         ]. Lower levels of platelet-derived microparticles and tissue factor-positive microparticles were seen in coagulopathic compared with noncoagulopathic trauma patients. A small study of 16 brain-injured patients also identified elevated levels of endothelial-, platelet-, and leukocyte-derived microparticles compared with controls [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Damage-associated molecular patterns
         </strong>
         – Multiple studies have also evaluated the association between damage-associated molecular patterns (DAMPs) and coagulation dysfunction, including specific evaluation of soluble receptor for advanced glycation end-products (RAGE) [
         <a href="#rid93">
          93
         </a>
         ], high-mobility group protein B1 (HMBG1) [
         <a href="#rid94">
          94
         </a>
         ], and mitochondrial DNA [
         <a href="#rid95">
          95,96
         </a>
         ]. Whether these or other DAMPs represent true biological mediators or simply correlate with measures of injury burden and coagulopathy is an active area of investigation [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3046566840">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severely injured trauma patients are routinely screened with standard laboratory evaluation, including complete blood count, serum electrolytes, arterial blood gas analysis, and standard coagulation tests. These laboratory studies provide an assessment of acidosis and hemodilution, indicate the severity of shock (as measured by base deficit and/or lactate levels), guide specific component blood product administration, and serve as a baseline for the assessment of ongoing hemorrhage. (See
         <a class="medical medical_review" href="/z/d/html/13854.html" rel="external">
          "Initial management of trauma in adults"
         </a>
         .)
        </p>
        <p>
         Readily obtainable coagulation tests (prothrombin time, international normalized ratio, and activated partial thromboplastin time) are the current standard for establishing a definitive diagnosis of coagulopathy. Fibrinogen and D-dimer levels are also available in most clinical laboratories and may serve as surrogate markers of clotting factor consumption and hyperfibrinolysis. (See
         <a class="medical medical_review" href="/z/d/html/1368.html" rel="external">
          "Clinical use of coagulation tests"
         </a>
         .)
        </p>
        <p>
         Although these assays are commonly relied upon to evaluate bleeding risk in trauma patients, these tests were originally designed to screen for heritable coagulopathies such as hemophilia and subsequently used to monitor anticoagulant therapy [
         <a href="#rid98">
          98
         </a>
         ]. The normal ranges are derived from the general population and correlate poorly with bleeding risk in elective general and vascular surgical operations [
         <a href="#rid99">
          99
         </a>
         ]. In addition, the results from standard laboratory analysis can take up to 30 minutes and may not accurately reflect the patient's evolving coagulation status. The processing delay may result in results that are irrelevant when they do become available, such as in the case of exsanguinating hemorrhage. As a result, there has been a trend toward the use of point-of-care laboratory testing (thromboelastography [TEG]) and clinical scoring systems to guide management of the severely injured patient. (See
         <a class="local">
          'Viscoelastic hemostatic assays'
         </a>
         below.)
        </p>
        <p>
         Patients with prolonged clotting times due to known bleeding diatheses or pharmacological anticoagulation are not traditionally defined as having trauma-induced coagulopathy, although TIC physiology may exacerbate any preexisting coagulation disorders. (See
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1324.html" rel="external">
          "Management of warfarin-associated bleeding or supratherapeutic INR"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1986427812">
         <span class="h2">
          Coagulation studies
         </span>
        </p>
        <p class="headingAnchor" id="H18982722">
         <span class="h3">
          Standard coagulation tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical studies have used several diagnostic criteria to identify clinically relevant coagulopathy following injury. These include prothrombin time (PT) &gt;18 seconds [
         <a href="#rid56">
          56
         </a>
         ], international normalized ratio (INR) &gt;1.5 [
         <a href="#rid100">
          100
         </a>
         ], activated partial thromboplastin time (PTT) &gt;60 seconds [
         <a href="#rid56">
          56
         </a>
         ], or any of these values at a threshold of 1.5 times the laboratory reference value [
         <a href="#rid101">
          101
         </a>
         ]. The prevalence of prolonged PT is higher, but prolongation of the PTT is more specific.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a trauma registry study involving 20,103 patients, the PT and PTT were prolonged in 28 and 8 percent of patients, respectively [
         <a href="#rid3">
          3
         </a>
         ]. The adjusted odds ratios for mortality were 1.35 for PT and 4.26 for PTT prolongation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A five-center international retrospective study of 3646 trauma patients identified patients with significantly greater transfusion requirements and increased mortality using a more liberal cutoff &gt;1.2 of prothrombin time ratio (an inter-center standardized version of the INR) [
         <a href="#rid102">
          102
         </a>
         ]. This lower INR value may be a more appropriate cutoff for patients with more severe injury (injury severity scale [ISS] &gt;15) and shock.
        </p>
        <p>
        </p>
        <p>
         Decreased platelet count and decreased platelet function also contribute to coagulopathy and poor outcome following trauma, although little information about platelet function is evident from the platelet count alone.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TEG, a holistic assessment of clot formation, reflects the contribution of platelet count and function to coagulation and may be modified to investigate platelet function specifically (see
         <a class="local">
          'Viscoelastic hemostatic assays'
         </a>
         below).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other instrumentation available to specifically assess platelet function includes the platelet function analyzer (PFA-100) and the electrical impedance whole blood aggregometer (Multiplate) [
         <a href="#rid103">
          103,104
         </a>
         ]. However, these devices have not been prospectively evaluated in trauma and resuscitation. (See
         <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">
          "Platelet function testing"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         It is unknown for certain whether TIC might exist in patients with normal-range values of PT/INR and PTT. There have been anecdotal reports of injured patients with clinically relevant hyperfibrinolysis identified using TEG but without prolonged PT or PTT. A careful study of markers of coagulopathy and inflammation in 80 trauma patients identified that increasing injury severity correlated with elevated markers of endothelial cell and glycocalyx damage, protein C activation, and clotting factor consumption even when INR and PTT values were in the normal range, suggesting that the biochemical derangement of TIC lies on a continuum dependent upon injury and shock severity [
         <a href="#rid58">
          58
         </a>
         ]. Thus, patients who present with the combination of significant injury (ISS &gt;15) and a base deficit (&lt;-6) should be closely monitored and aggressively treated for clinical coagulopathy even in the face of normal standard coagulation tests, pending further clinical studies. Because TIC can occur in patients with normal platelet and fibrinogen levels, specific platelet or fibrinogen levels are not included in current diagnostic criteria; however, when abnormalities are present, thrombocytopenia and hypofibrinogenemia certainly contribute to clinical hemorrhage and should be corrected [
         <a href="#rid2">
          2,3,17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3046566855">
         <span class="h3">
          Viscoelastic hemostatic assays
         </span>
         <span class="headingEndMark">
          —
         </span>
         TEG assesses the viscoelastic properties of clot formation in fresh or citrated whole blood in real time. The test synthesizes information obtained from multiple coagulation tests (PT, PTT, thrombin time, fibrinogen level, and platelet count) into a single readout  (
         <a class="graphic graphic_figure graphicRef80241" href="/z/d/graphic/80241.html" rel="external">
          figure 3
         </a>
         ) providing information regarding clot initiation, clot strength, and fibrinolysis simultaneously. The bulk of its clinical use has been as a point-of-care adjunct during cardiopulmonary bypass [
         <a href="#rid105">
          105
         </a>
         ], and liver transplantation [
         <a href="#rid106">
          106
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4433.html" rel="external">
          "Platelet function testing", section on 'Viscoelastic testing (TEG and ROTEM)'
         </a>
         .)
        </p>
        <p>
         As a functional test of clot formation and lysis, it is conceptually well suited to monitor the progress or resolution of coagulopathy after traumatic injury. TEG parameters have been validated against standard laboratory tests [
         <a href="#rid107">
          107,108
         </a>
         ], thrombin-antithrombin complex levels for TEG [
         <a href="#rid109">
          109
         </a>
         ], and euglobin clot lysis times for rotational thromboelastometry (ROTEM) [
         <a href="#rid110">
          110
         </a>
         ]. Specific elements of the clotting cascade can be interrogated by performing tests in the presence of specific clotting activators or inhibitors  (
         <a class="graphic graphic_table graphicRef55087" href="/z/d/graphic/55087.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
         Representative tracings compared with normal are given for each of the following abnormalities:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary fibrinolysis –  (
         <a class="graphic graphic_figure graphicRef58281 graphicRef51767" href="/z/d/graphic/58281.html" rel="external">
          figure 4A-B
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secondary hyperfibrinolysis –  (
         <a class="graphic graphic_figure graphicRef58281 graphicRef70388" href="/z/d/graphic/58281.html" rel="external">
          figure 4A, 4C
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thrombocytopenia –  (
         <a class="graphic graphic_figure graphicRef58281 graphicRef80926" href="/z/d/graphic/58281.html" rel="external">
          figure 4A, 4D
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clotting factor consumption –  (
         <a class="graphic graphic_figure graphicRef58281 graphicRef60690" href="/z/d/graphic/58281.html" rel="external">
          figure 4A, 4E
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypercoagulability –  (
         <a class="graphic graphic_figure graphicRef58281 graphicRef58977" href="/z/d/graphic/58281.html" rel="external">
          figure 4A, 4F
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Multiple studies have used TEG to diagnose immediate hypocoagulability and later hypercoagulability following moderate injury despite normal-range standard coagulation tests [
         <a href="#rid112">
          112,113
         </a>
         ]. Studies involving trauma patients have correlated TEG parameters with increased mortality [
         <a href="#rid114">
          114-118
         </a>
         ]. Cutoff values for ROTEM-based parameters correlate with standard laboratory transfusion cutoff values [
         <a href="#rid119">
          119
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3572831617">
         <span class="h4">
          TEG-based fibrinolytic phenotypes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Demonstrations of alterations in normal fibrinolysis following severe trauma, and the availability of TEG to facilitate their rapid diagnosis  (
         <a class="graphic graphic_figure graphicRef58281 graphicRef51767" href="/z/d/graphic/58281.html" rel="external">
          figure 4A-B
         </a>
         and
         <a class="graphic graphic_figure graphicRef70388" href="/z/d/graphic/70388.html" rel="external">
          figure 4C
         </a>
         ), have renewed an interest in antifibrinolytic therapy for the treatment of acute hemorrhage [
         <a href="#rid17">
          17,120-128
         </a>
         ].
        </p>
        <p>
         Early studies focused on empiric therapy and targeted management of hyperfibrinolysis [
         <a href="#rid121">
          121,129
         </a>
         ], noting that hyperfibrinolysis after injury was associated with increased mortality. In one study, the mortality rate for a group of patients who demonstrated hyperfibrinolysis was significantly greater compared with the group that did not demonstrate hyperfibrinolysis (77 versus 41 percent) [
         <a href="#rid117">
          117
         </a>
         ]. However, studies have identified two distinct injury-related fibrinolytic phenotypes apart from normal physiologic fibrinolysis, based on values of the TEG parameter LY30  (
         <a class="graphic graphic_table graphicRef74954" href="/z/d/graphic/74954.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef56058" href="/z/d/graphic/56058.html" rel="external">
          table 5
         </a>
         ):
        </p>
        <p class="headingAnchor" id="H2287228832">
         <span class="h5">
          Hyperfibrinolysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Excessive fibrinolytic activity leading to coagulopathy was originally noted during the anhepatic phase of liver transplantation [
         <a href="#rid130">
          130
         </a>
         ] and has subsequently been proposed to play a mechanistic role in TIC [
         <a href="#rid56">
          56,120
         </a>
         ]. The physiologic underpinning of hyperfibrinolysis appears to be primarily related to tissue plasminogen activator (tPA) release [
         <a href="#rid131">
          131
         </a>
         ], with an inadequate compensatory increase in antifibrinolytic plasminogen activator inhibitor-1 (PAI-1) [
         <a href="#rid132">
          132
         </a>
         ]. Animal models suggest that hyperfibrinolysis is mechanistically related to the degree of shock, while tissue injury appears to correlate with inhibition of fibrinolysis [
         <a href="#rid133">
          133
         </a>
         ]. A single-center prospective study of critically injured trauma patients identified an increase in risk of massive transfusion (91 versus 30 percent) and death due to hemorrhage (46 versus 5 percent) at an LY30 of 3 percent, which is a much lower target than the manufacturer-provided normal upper bound of 7.5 percent  (
         <a class="graphic graphic_table graphicRef56058" href="/z/d/graphic/56058.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_figure graphicRef80241" href="/z/d/graphic/80241.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid134">
          134
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3707275689">
         <span class="h5">
          Fibrinolysis shutdown
         </span>
         <span class="headingEndMark">
          —
         </span>
         Near-complete inhibition of fibrinolysis following elective surgery was also identified initially in early studies from the 1960s and 1970s and termed "shutdown" [
         <a href="#rid135">
          135,136
         </a>
         ]. A landmark prospective study of 180 injured patients characterized the incidence and outcomes of fibrinolysis shutdown after injury: fibrinolysis shutdown was the most prevalent phenotype (64 percent), compared with physiologic fibrinolysis (18 percent) and hyperfibrinolysis (18 percent) [
         <a href="#rid137">
          137
         </a>
         ]. An LY30 cutoff of 0.8 percent or less identified fibrinolysis shutdown in this study, derived from an analysis of the receiver-operator curve for mortality. A U-shaped distribution of mortality was identified across these phenotypes, with mortality rates of 17, 3, and 44 percent for patients presenting with shutdown, physiologic fibrinolysis, and hyperfibrinolysis, respectively. While the majority of deaths in the hyperfibrinolysis group were related to exsanguination, 40 percent of deaths in the shutdown group were attributed to multiple organ failure. These initial findings were subsequently recapitulated in a prospective cohort of more than 2500 injured patients from two large centers [
         <a href="#rid138">
          138
         </a>
         ]. Mechanistic study has so far shown that fibrinolysis shutdown is reproducible by the addition of platelet lysate in vitro and that it is attributable to tPA-binding activity based on chromatography [
         <a href="#rid133">
          133
         </a>
         ]; however, the physiologic underpinnings of shutdown remain an active area of investigation.
        </p>
        <p class="headingAnchor" id="H3622253202">
         <span class="h3">
          D-dimer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Elevated levels of D-dimer and other fibrin degradation products have been associated with severity of tissue damage, hyperfibrinolysis, and fibrinogen depletion early after injury [
         <a href="#rid139">
          139,140
         </a>
         ]. In a review of 519 adult trauma patients with an injury severity score ≥16, poor outcome (≥10 units of red cell concentrate transfusion and/or death during the first 24 hours) was optimally identified using cut-off fibrinogen and D-dimer values of 190 mg/dL and 38 mg/L, respectively. Survival was lower for high D-dimer/low fibrinogen group compared with other groups. High D-dimer level on arrival was a strong predictor of early death or requirement for massive transfusion in severe trauma patients, even with high fibrinogen levels. In a cohort study that included 940 patients, D-dimer levels were seven-fold higher among critically injured patients who died compared with those who survived (103,170 versus 13,672 ng/mL) [
         <a href="#rid141">
          141
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H971254456">
         <span class="h3">
          Fibrinogen levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fibrinogen is the terminal substrate for clot formation, and acquired fibrinogen deficiency in the setting of trauma is associated with hemorrhage and mortality [
         <a href="#rid142">
          142
         </a>
         ]. Correction of hypofibrinogenemia with cryoprecipitate or fibrinogen concentrates is advocated based on fibrinogen cut-offs, viscoelastic measures [
         <a href="#rid143">
          143
         </a>
         ], and empirically as part of massive transfusion protocols [
         <a href="#rid144">
          144
         </a>
         ]. Institutional practices vary widely, and strong clinical consensus about triggers for fibrinogen repletion has not yet been established [
         <a href="#rid145">
          145
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3046566862">
         <span class="h3">
          Factor levels
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although coagulation factors are not commonly assessed in injured patients, coagulation factor depletion due to hemodilution and unbalanced component blood transfusion exacerbates coagulopathy associated with trauma. Fibrinogen (factor I) is the first factor to become depleted, as noted above [
         <a href="#rid146">
          146
         </a>
         ]. Of the other commonly numbered coagulation factors, V and VIII are the most labile and may become selectively depleted during trauma resuscitation, particularly in the setting of low plasma to red blood cell unit transfusion ratios. In a multicenter observational study of 165 critically injured trauma patients with serial plasma clotting factor analysis, multivariate analysis identified deficits in fibrinogen, thrombin, Factor V, Factor VIII, Factor IX, Factor X, and activated protein C levels as age-, injury-, and shock-adjusted predictors of coagulopathy [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H749847339">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118154.html" rel="external">
          "Society guideline links: General issues of trauma management in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H62326854">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coagulopathy
         </strong>
         – Coagulopathy is associated with greater transfusion requirements, longer intensive care unit and hospital stays, more days of mechanical ventilation, and an increased incidence of multiorgan failure and mortality. The identification and early correction of coagulopathy is important to decrease fluid and transfusion requirements, decrease complications, and improve survival. (See
         <a class="local">
          'Impact'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Etiology
         </strong>
         – The etiology of coagulopathy in the injured patient is multifactorial with overlapping contributions from acidosis related to tissue injury and shock, hypothermia related to exposure and fluid administration, or hemodilution due to fluid or component blood product administration. In severely injured patients, an additional biochemical process that remains incompletely characterized underlies coagulopathy. Consumption of clotting factors manifesting as disseminated intravascular coagulation (DIC) may contribute upon presentation or later in the hospital course. (See
         <a class="local">
          'Etiologies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trauma-induced coagulopathy
         </strong>
         – Trauma-induced coagulopathy (TIC) is an impairment of hemostasis and activation of fibrinolysis that occurs in response to severe injury and is biochemically evident prior to, and independent of, the development of significant acidosis, hypothermia, or hemodilution. TIC is mediated primarily by activation of the thrombomodulin-protein C system. (See
         <a class="local">
          'Trauma-induced coagulopathy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Standard coagulation assays
         </strong>
         – Standard coagulation tests including prothrombin time/international normalized ratio (PT/INR), activated partial thromboplastin time (PTT), fibrinogen level, and platelet count are part of the initial laboratory evaluation of trauma patients. In patients without preexisting coagulation defects, a prolonged PT and/or activated PTT greater than 1.5 times normal on admission defines the presence of TIC. Clinically relevant TIC can occur in patients who have normal platelet and fibrinogen levels. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Viscoelastic hemostatic testing
         </strong>
         – Viscoelastic hemostatic testing (eg, thromboelastography [TEG], rotational thromboelastometry [ROTEM]) is an important tool for identifying patients with TIC and for real-time monitoring of ongoing resuscitation efforts in injured patients. TEG measures the viscoelastic properties of clot formation providing information on clot initiation, clot strength, and fibrinolysis. For patients requiring massive transfusion, we use early TEG-based goal-directed resuscitation and management of fibrinolysis rather than treatment based on standard coagulation assays, when the technology is available. At centers where TEG is not available, transfusion guided by standard coagulation assays remain standard of care. (See
         <a class="local">
          'Viscoelastic hemostatic assays'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma 2003; 54:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacLeod JB, Lynn M, McKenney MG, et al. Early coagulopathy predicts mortality in trauma. J Trauma 2003; 55:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maegele M, Lefering R, Yucel N, et al. Early coagulopathy in multiple injury: an analysis from the German Trauma Registry on 8724 patients. Injury 2007; 38:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang R, Cardenas JC, Wade CE, Holcomb JB. Advances in the understanding of trauma-induced coagulopathy. Blood 2016; 128:1043.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spivey M, Parr MJ. Therapeutic approaches in trauma-induced coagulopathy. Minerva Anestesiol 2005; 71:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess JR, Brohi K, Dutton RP, et al. The coagulopathy of trauma: a review of mechanisms. J Trauma 2008; 65:748.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore HB, Gando S, Iba T, et al. Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH. J Thromb Haemost 2020; 18:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang R, Kerby JD, Kalkwarf KJ, et al. Earlier time to hemostasis is associated with decreased mortality and rate of complications: Results from the Pragmatic Randomized Optimal Platelet and Plasma Ratio trial. J Trauma Acute Care Surg 2019; 87:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg 2008; 248:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinella PC, Perkins JG, Grathwohl KW, et al. Effect of plasma and red blood cell transfusions on survival in patients with combat related traumatic injuries. J Trauma 2008; 64:S69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holcomb JB, Jenkins D, Rhee P, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma 2007; 62:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yuan S, Ziman A, Anthony MA, et al. How do we provide blood products to trauma patients? Transfusion 2009; 49:1045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cinat ME, Wallace WC, Nastanski F, et al. Improved survival following massive transfusion in patients who have undergone trauma. Arch Surg 1999; 134:964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunter OL Jr, Au BK, Isbell JM, et al. Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival. J Trauma 2008; 65:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holcomb JB, Spinella PC. Optimal use of blood in trauma patients. Biologicals 2010; 38:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brohi K, Cohen MJ, Ganter MT, et al. Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway? Ann Surg 2007; 245:812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niles SE, McLaughlin DF, Perkins JG, et al. Increased mortality associated with the early coagulopathy of trauma in combat casualties. J Trauma 2008; 64:1459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demetriades D, Murray J, Martin M, et al. Pedestrians injured by automobiles: relationship of age to injury type and severity. J Am Coll Surg 2004; 199:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore FA, Nelson T, McKinley BA, et al. Is there a role for aggressive use of fresh frozen plasma in massive transfusion of civilian trauma patients? Am J Surg 2008; 196:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Lima Oliveira M, Kairalla AC, Fonoff ET, et al. Cerebral microdialysis in traumatic brain injury and subarachnoid hemorrhage: state of the art. Neurocrit Care 2014; 21:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee TH, Hampton DA, Diggs BS, et al. Traumatic brain injury is not associated with coagulopathy out of proportion to injury in other body regions. J Trauma Acute Care Surg 2014; 77:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castellino FJ, Chapman MP, Donahue DL, et al. Traumatic brain injury causes platelet adenosine diphosphate and arachidonic acid receptor inhibition independent of hemorrhagic shock in humans and rats. J Trauma Acute Care Surg 2014; 76:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutcher ME, Howard BM, Sperry JL, et al. Evolving beyond the vicious triad: Differential mediation of traumatic coagulopathy by injury, shock, and resuscitation. J Trauma Acute Care Surg 2015; 78:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Engström M, Schött U, Romner B, Reinstrup P. Acidosis impairs the coagulation: A thromboelastographic study. J Trauma 2006; 61:624.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martini WZ. Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability. J Trauma 2009; 67:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess JR. Blood and coagulation support in trauma care. Hematology Am Soc Hematol Educ Program 2007; :187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martini WZ, Dubick MA, Pusateri AE, et al. Does bicarbonate correct coagulation function impaired by acidosis in swine? J Trauma 2006; 61:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martini WZ, Dubick MA, Wade CE, Holcomb JB. Evaluation of tris-hydroxymethylaminomethane on reversing coagulation abnormalities caused by acidosis in pigs. Crit Care Med 2007; 35:1568.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wolberg AS, Meng ZH, Monroe DM 3rd, Hoffman M. A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function. J Trauma 2004; 56:1221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farkash U, Lynn M, Scope A, et al. Does prehospital fluid administration impact core body temperature and coagulation functions in combat casualties? Injury 2002; 33:103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kermode JC, Zheng Q, Milner EP. Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor. Blood 1999; 94:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lier H, Krep H, Schroeder S, Stuber F. Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma. J Trauma 2008; 65:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuei BJ, Kearney PA. Hypothermia in the trauma patient. Injury 2004; 35:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shafi S, Elliott AC, Gentilello L. Is hypothermia simply a marker of shock and injury severity or an independent risk factor for mortality in trauma patients? Analysis of a large national trauma registry. J Trauma 2005; 59:1081.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dirkmann D, Hanke AA, Görlinger K, Peters J. Hypothermia and acidosis synergistically impair coagulation in human whole blood. Anesth Analg 2008; 106:1627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schreiber MA. Coagulopathy in the trauma patient. Curr Opin Crit Care 2005; 11:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirshberg A, Dugas M, Banez EI, et al. Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation. J Trauma 2003; 54:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brazil EV, Coats TJ. Sonoclot coagulation analysis of in-vitro haemodilution with resuscitation solutions. J R Soc Med 2000; 93:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coats TJ, Brazil E, Heron M. The effects of commonly used resuscitation fluids on whole blood coagulation. Emerg Med J 2006; 23:546.
          </a>
         </li>
         <li class="breakAll">
          Whitaker, B, Sullivan, M. The 2005 Nationwide Blood Collection and Utilization Survey Report 2005. AABB. http://aabb.org/programs/biovigilance/nbcus/Documents/05nbcusrpt.pdf (Accessed on December 15, 2010).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358:1229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green RS, Erdogan M, Lacroix J, et al. Age of transfused blood in critically ill adult trauma patients: a prespecified nested analysis of the Age of Blood Evaluation randomized trial. Transfusion 2018; 58:1846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steiner ME, Ness PM, Assmann SF, et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med 2015; 372:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinella PC, Carroll CL, Staff I, et al. Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries. Crit Care 2009; 13:R151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heddle NM, Cook RJ, Arnold DM, et al. Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion. N Engl J Med 2016; 375:1937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacroix J, Hébert PC, Fergusson DA, et al. Age of transfused blood in critically ill adults. N Engl J Med 2015; 372:1410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardenas JC, Rahbar E, Pommerening MJ, et al. Measuring thrombin generation as a tool for predicting hemostatic potential and transfusion requirements following trauma. J Trauma Acute Care Surg 2014; 77:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess JR, Lawson JH. The coagulopathy of trauma versus disseminated intravascular coagulation. J Trauma 2006; 60:S12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gando S. Acute coagulopathy of trauma shock and coagulopathy of trauma: a rebuttal. You are now going down the wrong path. J Trauma 2009; 67:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levi M. Disseminated intravascular coagulation. Crit Care Med 2007; 35:2191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gando S, Saitoh D, Ogura H, et al. Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey. Crit Care Med 2008; 36:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86:1327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gando S, Tedo I, Kubota M. Posttrauma coagulation and fibrinolysis. Crit Care Med 1992; 20:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brohi K, Cohen MJ, Davenport RA. Acute coagulopathy of trauma: mechanism, identification and effect. Curr Opin Crit Care 2007; 13:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaz BH, Winkler AM, James AB, et al. Pathophysiology of early trauma-induced coagulopathy: emerging evidence for hemodilution and coagulation factor depletion. J Trauma 2011; 70:1401.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson PI, Sørensen AM, Perner A, et al. Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study. Crit Care 2011; 15:R272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cadroy Y, Diquélou A, Dupouy D, et al. The thrombomodulin/protein C/protein S anticoagulant pathway modulates the thrombogenic properties of the normal resting and stimulated endothelium. Arterioscler Thromb Vasc Biol 1997; 17:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chesebro BB, Rahn P, Carles M, et al. Increase in activated protein C mediates acute traumatic coagulopathy in mice. Shock 2009; 32:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esmon CT. Protein C pathway in sepsis. Ann Med 2002; 34:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen MJ, Call M, Nelson M, et al. Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients. Ann Surg 2012; 255:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen MJ, Kutcher M, Redick B, et al. Clinical and mechanistic drivers of acute traumatic coagulopathy. J Trauma Acute Care Surg 2013; 75:S40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276:15567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bajzar L, Jain N, Wang P, Walker JB. Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis. Crit Care Med 2004; 32:S320.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg 2011; 254:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gonzalez Rodriguez E, Ostrowski SR, Cardenas JC, et al. Syndecan-1: A Quantitative Marker for the Endotheliopathy of Trauma. J Am Coll Surg 2017; 225:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ostrowski SR, Johansson PI. Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy. J Trauma Acute Care Surg 2012; 73:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson PI, Stensballe J, Rasmussen LS, Ostrowski SR. High circulating adrenaline levels at admission predict increased mortality after trauma. J Trauma Acute Care Surg 2012; 72:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109:3161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finigan JH, Dudek SM, Singleton PA, et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280:17286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bae JS, Yang L, Manithody C, Rezaie AR. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood 2007; 110:3909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105:3178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuepbach RA, Feistritzer C, Fernández JA, et al. Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thromb Haemost 2009; 101:724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu J, Ji Y, Zhang X, et al. Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock. J Thromb Haemost 2009; 7:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finigan JH, Boueiz A, Wilkinson E, et al. Activated protein C protects against ventilator-induced pulmonary capillary leak. Am J Physiol Lung Cell Mol Physiol 2009; 296:L1002.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen MJ, Bir N, Rahn P, et al. Protein C depletion early after trauma increases the risk of ventilator-associated pneumonia. J Trauma 2009; 67:1176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ganter MT, Brohi K, Cohen MJ, et al. Role of the alternative pathway in the early complement activation following major trauma. Shock 2007; 28:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005; 131:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15:1318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davenport RA, Brohi K. Coagulopathy in trauma patients: importance of thrombocyte function? Curr Opin Anaesthesiol 2009; 22:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown LM, Call MS, Margaret Knudson M, et al. A normal platelet count may not be enough: the impact of admission platelet count on mortality and transfusion in severely injured trauma patients. J Trauma 2011; 71:S337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnüriger B, Inaba K, Abdelsayed GA, et al. The impact of platelets on the progression of traumatic intracranial hemorrhage. J Trauma 2010; 68:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutcher ME, Redick BJ, McCreery RC, et al. Characterization of platelet dysfunction after trauma. J Trauma Acute Care Surg 2012; 73:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briggs A, Gates JD, Kaufman RM, et al. Platelet dysfunction and platelet transfusion in traumatic brain injury. J Surg Res 2015; 193:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holzmacher JL, Reynolds C, Patel M, et al. Platelet transfusion does not improve outcomes in patients with brain injury on antiplatelet therapy. Brain Inj 2018; 32:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stettler GR, Moore EE, Moore HB, et al. Platelet adenosine diphosphate receptor inhibition provides no advantage in predicting need for platelet transfusion or massive transfusion. Surgery 2017; 162:1286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henriksen HH, Grand AG, Viggers S, et al. Impact of blood products on platelet function in patients with traumatic injuries: a translational study. J Surg Res 2017; 214:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vulliamy P, Kornblith LZ, Kutcher ME, et al. Alterations in platelet behavior after major trauma: adaptive or maladaptive? Platelets 2021; 32:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matijevic N, Wang YW, Wade CE, et al. Cellular microparticle and thrombogram phenotypes in the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study: correlation with coagulopathy. Thromb Res 2014; 134:652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nekludov M, Mobarrez F, Gryth D, et al. Formation of microparticles in the injured brain of patients with severe isolated traumatic brain injury. J Neurotrauma 2014; 31:1927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen MJ, Carles M, Brohi K, et al. Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans. J Trauma 2010; 68:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogel S, Bodenstein R, Chen Q, et al. Platelet-derived HMGB1 is a critical mediator of thrombosis. J Clin Invest 2015; 125:4638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmons JD, Lee YL, Mulekar S, et al. Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects. Ann Surg 2013; 258:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Billiar TR, Vodovotz Y. Time for trauma immunology. PLoS Med 2017; 14:e1002342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Owen CA Jr. Historical account of tests of hemostasis. Am J Clin Pathol 1990; 93:S3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eckman MH, Erban JK, Singh SK, Kao GS. Screening for the risk for bleeding or thrombosis. Ann Intern Med 2003; 138:W15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashuk JL, Moore EE, Johnson JL, et al. Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer? J Trauma 2008; 65:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoyt DB, Dutton RP, Hauser CJ, et al. Management of coagulopathy in the patients with multiple injuries: results from an international survey of clinical practice. J Trauma 2008; 65:755.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frith D, Goslings JC, Gaarder C, et al. Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations. J Thromb Haemost 2010; 8:1919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002; 9:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velik-Salchner C, Maier S, Innerhofer P, et al. Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study. Anesth Analg 2008; 107:1798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang Y. Thromboelastography in liver transplantation. Semin Thromb Hemost 1995; 21 Suppl 4:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeger V, Zimmermann H, Exadaktylos AK. Can RapidTEG accelerate the search for coagulopathies in the patient with multiple injuries? J Trauma 2009; 66:1253.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cotton BA, Faz G, Hatch QM, et al. Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission. J Trauma 2011; 71:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schreiber MA, Differding J, Thorborg P, et al. Hypercoagulability is most prevalent early after injury and in female patients. J Trauma 2005; 58:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levrat A, Gros A, Rugeri L, et al. Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients. Br J Anaesth 2008; 100:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chow JH, Richards JE, Morrison JJ, et al. Viscoelastic Signals for Optimal Resuscitation in Trauma: Kaolin Thrombelastography Cutoffs for Diagnosing Hypofibrinogenemia (VISOR Study). Anesth Analg 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufmann CR, Dwyer KM, Crews JD, et al. Usefulness of thrombelastography in assessment of trauma patient coagulation. J Trauma 1997; 42:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park MS, Martini WZ, Dubick MA, et al. Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time. J Trauma 2009; 67:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Inaba K, Rizoli S, Veigas PV, et al. 2014 Consensus conference on viscoelastic test-based transfusion guidelines for early trauma resuscitation: Report of the panel. J Trauma Acute Care Surg 2015; 78:1220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carroll RC, Craft RM, Langdon RJ, et al. Early evaluation of acute traumatic coagulopathy by thrombelastography. Transl Res 2009; 154:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöchl H, Frietsch T, Pavelka M, Jámbor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. J Trauma 2009; 67:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theusinger OM, Wanner GA, Emmert MY, et al. Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma. Anesth Analg 2011; 113:1003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tauber H, Innerhofer P, Breitkopf R, et al. Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'. Br J Anaesth 2011; 107:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rugeri L, Levrat A, David JS, et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Haemost 2007; 5:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashuk JL, Moore EE, Sawyer M, et al. Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma. Ann Surg 2010; 252:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CRASH-2 trial collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001; :CD001886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mangano DT, Tudor IC, Dietzel C, et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McMichan JC, Rosengarten DS, Philipp E. Prophylaxis of post-traumatic pulmonary insufficiency by protease-inhibitor therapy with aprotinin: a clinical study. Circ Shock 1982; 9:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ker K, Roberts I, Shakur H, Coats TJ. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2015; :CD004896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yutthakasemsunt S, Kittiwatanagul W, Piyavechvirat P, et al. Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial. BMC Emerg Med 2013; 13:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CRASH-2 Collaborators, Intracranial Bleeding Study. Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study). BMJ 2011; 343:d3795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CRASH-2 collaborators, Roberts I, Shakur H, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377:1096.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ. Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study. Arch Surg 2012; 147:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           STARZL TE, MARCHIORO TL, VONKAULLA KN, et al. HOMOTRANSPLANTATION OF THE LIVER IN HUMANS. Surg Gynecol Obstet 1963; 117:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman MP, Moore EE, Moore HB, et al. Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients. J Trauma Acute Care Surg 2016; 80:16.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardenas JC, Matijevic N, Baer LA, et al. Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients. Shock 2014; 41:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore HB, Moore EE, Gonzalez E, et al. Hemolysis exacerbates hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis: evolving concepts of the spectrum of fibrinolysis in response to severe injury. Shock 2015; 43:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapman MP, Moore EE, Ramos CR, et al. Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy. J Trauma Acute Care Surg 2013; 75:961.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chakrabarti R, Hocking ED, Fearnley GR. Reaction pattern to three stresses--electroplexy, surgery, and myocardial infarction--of fibrinolysis and plasma fibrinogen. J Clin Pathol 1969; 22:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths NJ. Factors affecting the fibrinolytic response to surgery. Ann R Coll Surg Engl 1979; 61:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore HB, Moore EE, Gonzalez E, et al. Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg 2014; 77:811.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore HB, Moore EE, Liras IN, et al. Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients. J Am Coll Surg 2016; 222:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayakawa M, Maekawa K, Kushimoto S, et al. HIGH D-DIMER LEVELS PREDICT A POOR OUTCOME IN PATIENTS WITH SEVERE TRAUMA, EVEN WITH HIGH FIBRINOGEN LEVELS ON ARRIVAL: A MULTICENTER RETROSPECTIVE STUDY. Shock 2016; 45:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagiwara S, Oshima K, Aoki M, et al. Usefulness of fibrin degradation products and d-dimer levels as biomarkers that reflect the severity of trauma. J Trauma Acute Care Surg 2013; 74:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gall LS, Vulliamy P, Gillespie S, et al. The S100A10 Pathway Mediates an Occult Hyperfibrinolytic Subtype in Trauma Patients. Ann Surg 2019; 269:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kornblith LZ, Kutcher ME, Redick BJ, et al. Fibrinogen and platelet contributions to clot formation: implications for trauma resuscitation and thromboprophylaxis. J Trauma Acute Care Surg 2014; 76:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schöchl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14:R55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Innerhofer P, Fries D, Mittermayr M, et al. Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial. Lancet Haematol 2017; 4:e258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spahn DR, Bouillon B, Cerny V, et al. The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition. Crit Care 2019; 23:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hiippala ST, Myllylä GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995; 81:360.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15147 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17132052" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Projections of global mortality and burden of disease from 2002 to 2030.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12813333" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Acute traumatic coagulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12855879" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Early coagulopathy predicts mortality in trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17214989" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Early coagulopathy in multiple injury: an analysis from the German Trauma Registry on 8724 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27381903" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Advances in the understanding of trauma-induced coagulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15886589" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Therapeutic approaches in trauma-induced coagulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18849786" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The coagulopathy of trauma: a review of mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32112533" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Defining trauma-induced coagulopathy with respect to future implications for patient management: Communication from the SSC of the ISTH.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31349348" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Earlier time to hemostasis is associated with decreased mortality and rate of complications: Results from the Pragmatic Randomized Optimal Platelet and Plasma Ratio trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18791365" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18376175" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Effect of plasma and red blood cell transfusions on survival in patients with combat related traumatic injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17297317" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Damage control resuscitation: directly addressing the early coagulopathy of trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19389035" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : How do we provide blood products to trauma patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10487591" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Improved survival following massive transfusion in patients who have undergone trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18784564" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Optimizing outcomes in damage control resuscitation: identifying blood product ratios associated with improved survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20074980" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Optimal use of blood in trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17457176" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18545109" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Increased mortality associated with the early coagulopathy of trauma in combat casualties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15325607" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pedestrians injured by automobiles: relationship of age to injury type and severity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19095115" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Is there a role for aggressive use of fresh frozen plasma in massive transfusion of civilian trauma patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24072457" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cerebral microdialysis in traumatic brain injury and subarachnoid hemorrhage: state of the art.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24977757" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Traumatic brain injury is not associated with coagulopathy out of proportion to injury in other body regions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24747445" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Traumatic brain injury causes platelet adenosine diphosphate and arachidonic acid receptor inhibition independent of hemorrhagic shock in humans and rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25710421" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Evolving beyond the vicious triad: Differential mediation of traumatic coagulopathy by injury, shock, and resuscitation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16966998" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Acidosis impairs the coagulation: A thromboelastographic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19590336" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14608161" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18024628" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Blood and coagulation support in trauma care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16832255" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Does bicarbonate correct coagulation function impaired by acidosis in swine?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17452929" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Evaluation of tris-hydroxymethylaminomethane on reversing coagulation abnormalities caused by acidosis in pigs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15211129" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A systematic evaluation of the effect of temperature on coagulation enzyme activity and platelet function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11890910" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Does prehospital fluid administration impact core body temperature and coagulation functions in combat casualties?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10381514" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Marked temperature dependence of the platelet calcium signal induced by human von Willebrand factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18849817" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Preconditions of hemostasis in trauma: a review. The influence of acidosis, hypocalcemia, anemia, and hypothermia on functional hemostasis in trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14728949" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Hypothermia in the trauma patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16385283" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Is hypothermia simply a marker of shock and injury severity or an independent risk factor for mortality in trauma patients? Analysis of a large national trauma registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18499589" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Hypothermia and acidosis synergistically impair coagulation in human whole blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16292065" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Coagulopathy in the trauma patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12634523" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Minimizing dilutional coagulopathy in exsanguinating hemorrhage: a computer simulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11064686" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Sonoclot coagulation analysis of in-vitro haemodilution with resuscitation solutions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16794099" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The effects of commonly used resuscitation fluids on whole blood coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16794099" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The effects of commonly used resuscitation fluids on whole blood coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18354101" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Duration of red-cell storage and complications after cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29672869" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Age of transfused blood in critically ill adult trauma patients: a prespecified nested analysis of the Age of Blood Evaluation randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25853746" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Effects of red-cell storage duration on patients undergoing cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19772604" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27775503" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Effect of Short-Term vs. Long-Term Blood Storage on Mortality after Transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25853745" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Age of transfused blood in critically ill adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25099452" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Measuring thrombin generation as a tool for predicting hemostatic potential and transfusion requirements following trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16763475" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The coagulopathy of trauma versus disseminated intravascular coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19667894" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Acute coagulopathy of trauma shock and coagulopathy of trauma: a rebuttal. You are now going down the wrong path.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17855836" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Disseminated intravascular coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18090367" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Natural history of disseminated intravascular coagulation diagnosed based on the newly established diagnostic criteria for critically ill patients: results of a multicenter, prospective survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11816725" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1533358" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Posttrauma coagulation and fibrinolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17975390" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Acute coagulopathy of trauma: mechanism, identification and effect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21460741" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pathophysiology of early trauma-induced coagulopathy: emerging evidence for hemodilution and coagulation factor depletion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22087841" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9102171" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The thrombomodulin/protein C/protein S anticoagulant pathway modulates the thrombogenic properties of the normal resting and stimulated endothelium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19333141" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Increase in activated protein C mediates acute traumatic coagulopathy in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12553500" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Protein C pathway in sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22133894" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Critical role of activated protein C in early coagulopathy and later organ failure, infection and death in trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23778510" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Clinical and mechanistic drivers of acute traumatic coagulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11264280" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15118538" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Thrombin activatable fibrinolysis inhibitor: not just an inhibitor of fibrinolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21772125" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28579548" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Syndecan-1: A Quantitative Marker for the Endotheliopathy of Trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22743373" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Endothelial glycocalyx degradation induces endogenous heparinization in patients with severe injury and early traumatic coagulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22439205" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : High circulating adrenaline levels at admission predict increased mortality after trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17110453" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The cytoprotective protein C pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15710622" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17823308" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15626732" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19350118" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19320827" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19363121" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Activated protein C protects against ventilator-induced pulmonary capillary leak.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20009664" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Protein C depletion early after trauma increases the risk of ventilator-associated pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17510601" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Role of the alternative pathway in the early complement activation following major trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16715088" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Generation of C5a in the absence of C3: a new complement activation pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16281932" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The interactions between inflammation and coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19855397" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Extracellular histones are major mediators of death in sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19390252" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Coagulopathy in trauma patients: importance of thrombocyte function?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21814101" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : A normal platelet count may not be enough: the impact of admission platelet count on mortality and transfusion in severely injured trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20386283" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : The impact of platelets on the progression of traumatic intracranial hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22743367" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Characterization of platelet dysfunction after trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25218281" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Platelet dysfunction and platelet transfusion in traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29341793" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Platelet transfusion does not improve outcomes in patients with brain injury on antiplatelet therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28964508" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Platelet adenosine diphosphate receptor inhibition provides no advantage in predicting need for platelet transfusion or massive transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28624038" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Impact of blood products on platelet function in patients with traumatic injuries: a translational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31986948" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Alterations in platelet behavior after major trauma: adaptive or maladaptive?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25086657" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Cellular microparticle and thrombogram phenotypes in the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study: correlation with coagulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24956150" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Formation of microparticles in the injured brain of patients with severe isolated traumatic brain injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20539169" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Early release of soluble receptor for advanced glycation endproducts after severe trauma in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26551681" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Platelet-derived HMGB1 is a critical mediator of thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20203610" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Circulating mitochondrial DAMPs cause inflammatory responses to injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23979273" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28700602" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Time for trauma immunology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2180278" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Historical account of tests of hemostasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12558384" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Screening for the risk for bleeding or thrombosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18695460" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Postinjury life threatening coagulopathy: is 1:1 fresh frozen plasma:packed red blood cells the answer?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18849787" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Management of coagulopathy in the patients with multiple injuries: results from an international survey of clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20553376" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Definition and drivers of acute traumatic coagulopathy: clinical and experimental investigations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12172459" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Clinical application of the PFA-100.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19020120" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Point-of-care whole blood impedance aggregometry versus classical light transmission aggregometry for detecting aspirin and clopidogrel: the results of a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9972747" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8747686" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Thromboelastography in liver transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19359945" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Can RapidTEG accelerate the search for coagulopathies in the patient with multiple injuries?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21825945" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Rapid thrombelastography delivers real-time results that predict transfusion within 1 hour of admission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15761339" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Hypercoagulability is most prevalent early after injury and in female patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18440953" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Evaluation of rotation thrombelastography for the diagnosis of hyperfibrinolysis in trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31306242" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Viscoelastic Signals for Optimal Resuscitation in Trauma: Kaolin Thrombelastography Cutoffs for Diagnosing Hypofibrinogenemia (VISOR Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9137263" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Usefulness of thrombelastography in assessment of trauma patient coagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19667878" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Thromboelastography as a better indicator of hypercoagulable state after injury than prothrombin time or activated partial thromboplastin time.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26151526" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : 2014 Consensus conference on viscoelastic test-based transfusion guidelines for early trauma resuscitation: Report of the panel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19524872" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Early evaluation of acute traumatic coagulopathy by thrombelastography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19590321" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21918164" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Hyperfibrinolysis diagnosed by rotational thromboelastometry (ROTEM) is associated with higher mortality in patients with severe trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21705350" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17109736" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20739843" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Primary fibrinolysis is integral in the pathogenesis of the acute coagulopathy of trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20554319" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11279735" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16436767" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : The risk associated with aprotinin in cardiac surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6177441" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Prophylaxis of post-traumatic pulmonary insufficiency by protease-inhibitor therapy with aprotinin: a clinical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25956410" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Antifibrinolytic drugs for acute traumatic injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24267513" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Tranexamic acid for patients with traumatic brain injury: a randomized, double-blinded, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21724564" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Effect of tranexamic acid in traumatic brain injury: a nested randomised, placebo controlled trial (CRASH-2 Intracranial Bleeding Study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21439633" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22006852" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Military Application of Tranexamic Acid in Trauma Emergency Resuscitation (MATTERs) Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14100514" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : HOMOTRANSPLANTATION OF THE LIVER IN HUMANS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26491796" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Overwhelming tPA release, not PAI-1 degradation, is responsible for hyperfibrinolysis in severely injured trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24667610" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Elevated tissue plasminogen activator and reduced plasminogen activator inhibitor promote hyperfibrinolysis in trauma patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25072794" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Hemolysis exacerbates hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis: evolving concepts of the spectrum of fibrinolysis in response to severe injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24256667" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Fibrinolysis greater than 3% is the critical value for initiation of antifibrinolytic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5365337" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Reaction pattern to three stresses--electroplexy, surgery, and myocardial infarction--of fibrinolysis and plasma fibrinogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/84546" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Factors affecting the fibrinolytic response to surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25051384" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26920989" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Acute Fibrinolysis Shutdown after Injury Occurs Frequently and Increases Mortality: A Multicenter Evaluation of 2,540 Severely Injured Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26882403" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : HIGH D-DIMER LEVELS PREDICT A POOR OUTCOME IN PATIENTS WITH SEVERE TRAUMA, EVEN WITH HIGH FIBRINOGEN LEVELS ON ARRIVAL: A MULTICENTER RETROSPECTIVE STUDY.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23609278" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Usefulness of fibrin degradation products and d-dimer levels as biomarkers that reflect the severity of trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31082919" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : The S100A10 Pathway Mediates an Occult Hyperfibrinolytic Subtype in Trauma Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24458031" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Fibrinogen and platelet contributions to clot formation: implications for trauma resuscitation and thromboprophylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20374650" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28457980" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : Reversal of trauma-induced coagulopathy using first-line coagulation factor concentrates or fresh frozen plasma (RETIC): a single-centre, parallel-group, open-label, randomised trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30917843" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7542432" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
